Who owns Vor Biopharma Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of VOR from SEC Form 13F filings across 156 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 156 institutions disclosed 55.3M shares of Vor Biopharma Inc. worth $1.06B — about 92.7% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
156
13F holders
$1.06B
value, 2026 filers
92.7%
of shares outstanding (55.3M sh)
67
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of VOR's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 6.8M | $129.0M | 0.0% | 11.3% | +37.0% |
| 2 | TCG Crossover Management, LLC | 5.7M | $108.2M | 3.1% | 9.5% | 0.0% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 4.5M | $85.9M | 0.9% | 7.5% | +87.5% |
| 4 | FCPM III SERVICES B.V. | 3.4M | $65.0M | 6.1% | 5.7% | -17.3% |
| 5 | BlackRock, Inc. | 3.3M | $63.1M | 0.0% | 5.5% | -4.7% |
| 6 | Venrock Adviser, LLC | 3.0M | $58.0M | 2.8% | 5.1% | 0.0% |
| 7 | Frazier Life Sciences Management, L.P. | 2.7M | $52.4M | 1.3% | 4.6% | +7.9% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $38.8M | 0.0% | 3.4% | -2.3% |
| 9 | STATE STREET CORP | 2.0M | $37.6M | 0.0% | 3.3% | -24.7% |
| 10 | Caligan Partners LP | 1.9M | $36.7M | 2.2% | 3.2% | 0.0% |
| 11 | GREAT POINT PARTNERS LLC | 1.1M | $21.5M | 5.1% | 1.9% | -33.7% |
| 12 | MILLENNIUM MANAGEMENT LLC | 991,532 | $18.9M | 0.0% | 1.7% | +131.6% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 979,890 | $18.7M | 0.0% | 1.6% | -7.8% |
| 14 | Nantahala Capital Management, LLC | 931,644 | $17.8M | 0.6% | 1.6% | +10.3% |
| 15 | Paradigm Biocapital Advisors LP | 889,575 | $17.0M | 0.3% | 1.5% | -49.2% |
| 16 | FEDERATED HERMES, INC.NEW | 760,221 | $14.5M | 0.0% | 1.3% | new |
| 17 | GOLDMAN SACHS GROUP INC | 746,214 | $14.2M | 0.0% | 1.3% | +126.9% |
| 18 | NAN FUNG TRINITY (HK) LTD | 721,550 | $13.8M | 1.3% | 1.2% | +11.6% |
| 19 | BOOTHBAY FUND MANAGEMENT, LLC | 646,521 | $12.3M | 0.2% | 1.1% | +15.7% |
| 20 | NEXTBio Capital Management LP | 620,931 | $11.8M | 5.1% | 1% | -30.2% |
| 21 | Rosalind Advisors, Inc. | 609,199 | $11.6M | 3.7% | 1% | -6.1% |
| 22 | UBS Group AG | 583,666 | $11.1M | 0.0% | 1% | +18.3% |
| 23 | MARSHALL WACE, LLP | 560,715 | $10.7M | 0.0% | 0.9% | +486.3% |
| 24 | Vivo Capital, LLCNEW | 550,358 | $10.5M | 1.2% | 0.9% | new |
| 25 | AMERIPRISE FINANCIAL INCNEW | 537,150 | $10.2M | 0.0% | 0.9% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.